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Abstract
Background: The aim of the study was to compare the prevalence and types of HIV-related oral lesions between
children and adult Tanzanian patients on HAART with those not on HAART and to relate the occurrence of the lesions
with anti-HIV drug regimen, clinical stage of HIV disease and CD4+ cell count.
Methods: Participants were 532 HIV infected patients, 51 children and 481 adults, 165 males and 367 females. Children
were aged 2–17 years and adults 18 and 67 years. Participants were recruited consecutively at the Muhimbili National
Hospital (MNH) HIV clinic from October 2004 to September 2005. Investigations included; interviews, physical
examinations, HIV testing and enumeration of CD4+ T cells.
Results: A total of 237 HIV-associated oral lesions were observed in 210 (39.5%) patients. Oral candidiasis was the
commonest (23.5%), followed by mucosal hyperpigmentation (4.7%). There was a significant difference in the occurrence
of oral candidiasis (χ2 = 4.31; df = 1; p = 0.03) and parotid enlargement (χ2 = 36.5; df = 1; p = 0.04) between children and
adults. Adult patients who were on HAART had a significantly lower risk of; oral lesions (OR = 0.32; 95% CI = 0.22 –
0.47; p = 0.005), oral candidiasis (OR = 0.28; 95% CI = 0.18 – 0.44; p = 0.003) and oral hairy leukoplakia (OR = 0.18; 95%
CI = 0.04 – 0.85; p = 0.03). There was no significant reduction in occurrence of oral lesions in children on HAART (OR
= 0.35; 95% CI = 0.11–1.14; p = 0.15). There was also a significant association between the presence of oral lesions and
CD4+ cell count < 200 cell/mm3 (χ2 = 52.4; df = 2; p = 0.006) and with WHO clinical stage (χ2 = 121; df = 3; p = 0.008).
Oral lesions were also associated with tobacco smoking (χ2 = 8.17; df = 2; p = 0.04).
Conclusion: Adult patients receiving HAART had a significantly lower prevalence of oral lesions, particularly oral
candidiasis and oral hairy leukoplakia. There was no significant change in occurrence of oral lesions in children receiving
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HAART. The occurrence of oral lesions, in both HAART and non-HAART patients, correlated with WHO clinical staging
and CD4+ less than 200 cells/mm3.
Background
Most African studies on HIV associated oral lesions have
been done during pre-HAART era [1-11]. The relatively
few studies of oral lesions in patients on HAART have
been conducted elsewhere and do indicate significant dif-
ferences in the influence of HAART on types of oral
lesions [12-14]. For example, oral candidiasis, oral hairy
leukoplakia, Kaposi's sarcoma and HIV-associated perio-
dontal diseases have been reported to decrease [12,13,15-
22]. On the other hand, HIV-salivary gland disease,
human papilloma virus (HPV)-associated oral lesions
including papilloma, condylomas and focal epithelial
hyperplasia [oral warts], xerostomia and recurrent oral
ulceration appear to have increased [13-15,18,23-25].
There are also reports indicating no change in the occur-
rence of HIV associated oral lesions in children receiving
HAART [26,27]. The reasons for these differences are not
entirely clear. Some authors have associated these varia-
tions with differences in access to oral health care, demo-
graphic and social factors, mode of HIV transmission,
types of co-infections, disease stage and immune reconsti-
tution [18,28,29]. Nonetheless, the presence of such sig-
nificant differences underlines the need for meticulous
monitoring of prevalence and types of HIV associated oral
lesions in every clinical setting that provide HAART [13].
As indicated earlier, most of the above-mentioned studies
have been conducted in developed countries [30,31].
There is relatively little information emanating from
developing countries, where particular efforts are being
made to scale up provision of HAART to eligible patients
[32].
The government of Tanzania, with assistance from inter-
national donor agencies, started providing HAART to HIV
patients free of charge in July 2004 [33,34]. However,
there is no information regarding human immunodefi-
ciency virus (HIV)-related oral lesions of patients on
antiretroviral therapy. This study aimed to determine the
prevalence and types of oral manifestations of HIV/AIDS
between children and adult patients on HAART and those
not on HAART, and correlate clinical oral lesions with
clinical stage of HIV disease, anti-HIV drug regimen and
CD4+ cell count.
Methods
Participants and setting
A total of 532 HIV-infected patients, 367 (69%) females
and 165 (31%) males participated in the study. There
were 51 children aged between 2 and 17 years, with mean
age of 7.6 (SD ± 4.3) years and 481 adults aged 18–67
years, with a mean age of 38.2 (SD ± 8.9) years. Partici-
pants were recruited consecutively at the Muhimbili
National Hospital (MNH) HIV clinic in Dar es Salaam,
from October 2004 to September 2005. The MNH is the
largest referral hospital in Tanzania and serves as a teach-
ing facility for the Muhimbili University College of Health
Sciences (MUCHS), the largest medical school in the
country.
Study design and sample size calculations
This was a cross sectional study. The sample size was esti-
mated at 336, by assuming the prevalence of oral lesions
in HIV infected individuals in Tanzania to be around 30%
[4] and by setting type I error at 5% and type II error at
20%. We consecutively enrolled 532 patients. None of the
patients declined participation in this study, bringing the
participation rate to 100%.
Investigations
Patients were interviewed using a standard structured
questionnaire to obtain information regarding social and
demographic details, past medical history, family history
and history of previous medication. Previous episodes of
oral candidiasis, other medical conditions, use of tradi-
tional medicine, anti-tuberculosis drugs, antifungal
agents, and use of antiretroviral and current treatments
were all recorded. Current and previous episodes of
opportunistic systemic diseases related to HIV were cate-
gorized and recorded as follows: tuberculosis, pneumo-
nia, herpes zoster infection and cryptococcal meningitis.
General examination
Clinical examination of all study patients was done by an
independent physician, who categorized them in accord-
ance with the World Health Organization (WHO) clinical
staging criteria [35].
Oral examination
An oral examination was carried out by a qualified dental
surgeon without knowing the HIV clinical stage and
CD4+ cell count level of the patient or whether the patient
was on HAART or not. A standard oral examination
method recommended by WHO [36] was used to exam-
ine: (a) the extra-oral, head and neck areas; and (b), peri-
oral and intra-oral soft tissues using a criteria described by
Greenspan et al. [37]. Examination was conducted while
the patient was seated on a chair under artificial light. The
extra-oral and peri-oral tissues were examined first, fol-
lowed by the intra-oral tissues, for changes in size, colourBMC Oral Health 2006, 6:12 http://www.biomedcentral.com/1472-6831/6/12
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and shape of anatomical areas as well as for clinical signs
and lesions. The oral lesions associated with HIV infection
were diagnosed based on their clinical presentation and
where multiple sites were involved, all sites were docu-
mented.
HIV serology and determination of lymphocytes subsets
Blood was collected in EDTA tubes from the patients. HIV
serology was determined by Vironostika HIV Uni-Form II
Ag/Ab (BioMerieux, Boxtel, The Netherlands) and reactive
samples were retested by Vironostika HIV Uni-Form II
Plus O (BioMerieux, Boxtel, The Netherlands). Samples
reactive on both tests were considered to be positive for
IgG anti HIV antibodies. Enumeration of CD4+ and CD8+
T cells was done using FACS count machine after staining
patients' blood with monoclonal antibodies [38].
HAART regimens
In Tanzanian setting, a triple therapy consisting of 2 nucl-
eoside reverse transcriptase inhibitors (NRTI) + 1 non-
nucleoside reverse transcriptase inhibitors (NNRTI) or 2
NRTI + 1 Protease inhibitor (PI) is recommended. The
first line includes four different combinations of drugs:
stavudine + lamivudine + nevirapine; stavudine + lamivu-
dine + effavirenz; zidovudine + lamivudine + nevirapine
and zidovudine + lamivudine + effavirenz. The second
line regimen includes the following drug combination:
Abacavir + kaletra (lopinavir/ritonavir) + didanosine and
abacavir + saquinavir/ritonavir + didanosine [34].
Ethical issues
The study protocol was approved by the ethics commit-
tees of the Muhimbili University College of Health Sci-
ences and Muhimbili National Hospital, Dar es salaam,
Tanzania. Informed verbal consent was sought from par-
ticipants and from parents/or guardians in case of chil-
dren below eighteen years. The following information was
given to ensure that patients and parents/guardians have
the information needed to make an informed choice: a
complete description of the aims of the study, potential
benefits and risks, blood collection procedures and assur-
ance of confidentiality of any information given as well as
test results. Study personnel provided any other requested
additional information. All patients seen in this study
received appropriate care and treatment according to
national guidelines on care and treatment of HIV infected
individuals. Patients who were found to have any oral
lesions were referred to the Department of Oral Surgery
and Oral Pathology of the Muhimbili National Hospital
where appropriate management and follow-up were
given. All patients' information and test results were con-
fidentially kept.
Statistical analysis
Data were coded, entered, cleaned, validated and ana-
lyzed using the SPSS version 12.0 [39]. Patients were cate-
gorized into children (<18 years) and adults (≥18 years)
and into those on HAART and those not receiving HAART.
Comparison of proportions was performed using the
Pearson chi-squared test and in situation where 20% or
more of the cells had expected count less than 5, Fisher's
exact test was used. Bivariate analysis was done using
Spearman's rank correlations. A P-value of < 0.05 was con-
sidered significant. The following were determined:
degree of associations between occurrence and types of
oral lesions and use of anti-retrovirals, gender, smoking
habits, alcohol consumption, coexistence with opportun-
istic systemic diseases, clinical stage of HIV disease and
degree of immunosuppression. Multiple logistic regres-
sion analysis was performed to assess the association
between presence of oral lesion associated with HIV and
use of antiretrovirals after adjusting for CD4+ cell count.
Results
A total of 532 HIV-infected patients, 367 (69%) females
and 165 (31%) males participated in the study (Table 1).
There were 51 children aged between 2 and 17 years, with
mean age of 7.6 (SD ± 4.3) years and 481 adults aged 18–
67 years, with a mean age of 38.2 (SD ± 8.9) years. Over-
all, median CD4+ cell count was 151 cells/mm3, with val-
ues ranging from 1 to 2007 cell/mm3. The median CD4+
cell count for children was 501 cells/mm3 and 134 cells/
mm3 for adults. Majority 373 (70.1%) of children and
adult patients were in the WHO clinical stages II to III.
Among the participants, 298 (56%) patients were on
HAART, consisting of nucleoside reverse transcriptase
inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs) and protease inhibitors (PIs). Major-
ity 531 (99.7%) were on the first line HAART combina-
tion, of whom 229 (76.8%) were on a combination of
Stavudine/Lamivudine/Nevirapine, 32 (10.7%) on a
combination of Zidovudine/Lamivudine/Effavirenz, 26
(8.7%) on Stavudine/Lamivudine/Effavirenz and 10
(3.4%) were on Zidovudine/Lamivudine/Nevirapine.
One patient (0.3%) was on second line combination that
included protease inhibitors (Abacavir/Lopinavir/Dida-
nosine). Two hundred and thirty four (44%) patients
were not receiving HAART. Sixty-two patients (11.7%)
reported use of traditional medicines, of whom 36 (58%)
were concomitantly using traditional medicines with
HAART.
A total of 237 HIV-associated oral lesions were observed
in 210 (39.5%) patients. Overall, oral candidiasis was the
commonest oral lesion seen in 125 (23.5%) patients fol-
lowed by mucosal hyper pigmentation 25 (4.7%), parotid
gland enlargement 21 (3.9%) and oral Kaposi's sarcoma
17 (3.2%) (Table 2). In children, parotid gland enlarge-BMC Oral Health 2006, 6:12 http://www.biomedcentral.com/1472-6831/6/12
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ment was the commonest oral lesion (19.6%), followed
by oral candidiasis (11.8%), oral Kaposi's sarcoma
(3.9%), oral hairy leukoplakia (3.9%), herpes simplex
lesions (2.2%) and oral warts was the least (2.0%). In
adults, oral candidiasis was the commonest (24.7%), fol-
lowed by mucosal hyperpigmentation (5.2%), herpes
zoster face and odontogenic abscess was the least (0.4%
each). There was statistically significant difference in the
occurrence of oral candidiasis (X2 = 4.31; df = 1; p < 0.05)
and parotid enlargement (X2 = 36.5; df = 1; p < 0.05)
between children and adults. Pseudomembranous candi-
diasis was the most predominant type of oral candidiasis
66.4% (83/125) followed by a combination of pseu-
domembranous and erythematous 12% (15/125), ery-
thematous candidiasis 9.6% (12/125), angular cheilitis
3.2% (4/125), combination of angular cheilitis with ery-
thematous and hyperplastic variant were the least (1.6%
each). Among 125 patients diagnosed with oral candidia-
sis 42 (33.6%) patients had previous history of oral can-
didiasis, 37 (29.6%) patients presented with esophageal
symptoms such as dysphagia, odynophagia and chest
pain at the time of examination.
Table 3 shows no significant difference in prevalence of
oral lesions among children on HAART and those not on
HAART (OR = 0.35; 95% CI = 0.11 – 1.15; p > 0.05). Table
4 shows that adult patients who were on HAART had a sig-
nificantly lower risk of oral lesions (OR = 0.32; 95% CI =
0.22–0.47; p < 0.01), oral candidiasis (OR = 0.28; 95% CI
= 0.18 – 0.44; p < 0.01) and oral hairy leukoplakia (OR =
0.18; 95% CI = 0.04 – 0.85; p < 0.03). There was also
lower prevalence of necrotizing ulcerative gingivitis, her-
pes simplex lesions, recurrent ulcers, Bell's palsy and her-
pes zoster of face in adult patients who were on HAART,
Table 1: Socio-demographic, treatment, WHO clinical stage and CD4 cell counts of study participants
Characteristics All patients n (%) Patients with oral lesions n (%)* χ2-value p-value**
Gender
Male 165 (31.0) 63 (38.2) 0.17 0.68
Female 367 (69.0) 147 (40.1)
Age (Years)
Children 2–17 51 (9.6) 21 (41.2) 0.68 0.88
Adults 18 – 67 481 (90.4) 189 (39.3)
Smoking habit
Current 20 (3.8) 14 (70) 8.17 0.02
Stopped 17 (3.2) 7 (41.2)
Never 495 (93.0) 189 (38.2)
Alcohol consumption
Current 31 (5.8) 10 (32.3)
Stopped 37 (7.0) 16 (43.2) 0.90 0.64
Never 464 (87.2) 184 (39.6)
Traditional medicine
Yes 62 (11.7) 25 (40.3) 0.17 0.68
No 470 (88.3) 183 (38.9)
Antiretroviral therapy
Without therapy 234 (44.0) 127 (54.3) 38.30 0.00
HAART therapy 298 (56.0) 83 (27.9)
Antiretroviral types
Stav/Lamiv/Nev 229 (76.8) 9 (12.9) 2.96 0.57
Stav/Lamiv/Eff 26 (8.7) 10 (38.5)
Zido/Lamiv/Eff 32 (10.7) 11 (34.4)
Zido/Lamiv/Nev 10 (3.4) 2 (20.0)
Abac/Lop/Didan 1 (0.3) 0 (0)
WHO HIV clinical stage
Stage I 70 (13.2) 9 (12.9)
Stage II 204 (38.3) 38 (18.6) 120.93 0.00
Stage III 169 (31.8) 101 (59.8)
Stage IV 89 (16.7) 62 (69.7)
CD4+ cell count (cells/mm3)
> 500 46 (8.6) 10 (21.7)
200–500 164 (30.8) 33 (20.5) 52.45 0.00
< 200 322 (60.5) 167 (31.9)
Total number of patients 532 (100.) 210 (39.5)
* Row percentages; ** p-value less than 0.05 was considered significant; χ2 Chi square testBMC Oral Health 2006, 6:12 http://www.biomedcentral.com/1472-6831/6/12
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but the difference was not statistically significant (p >
0.05). After controlling for CD4+ cell count, adult on
HAART had a significantly lower risk of oral Kaposi's sar-
coma compared with those not on HAART (adjusted OR
= 0.29; 95% CI = 0.10–0.89; p < 0.03). The odds for oral
warts and mucosal hyper pigmentation were non-signifi-
cant higher in adult who were on HAART, being (OR =
1.49; 95% CI = 0.13 – 16.5; p > 0.05) and (OR = 1.62;
95% CI = 0.68 – 3.82; p > 0.05), respectively.
The duration of use of HAART ranged from 1 to 14
months, with majority (71.1%) having been on treatment
for one to six months. Patients on HAART for the duration
of more than six months had significantly lower preva-
lence of oral lesions (OR = 0.53; 95% CI 0.29–0.97; p <
0.05) and specifically oral candidiasis (OR = 0.53; 95% CI
0.29–0.97; p = 0.04).
The mean CD4+ profiles of patients on HAART and those
not on HAART are shown in Table 5. Overall, the majority
(67.8%) of patients who were on HAART had CD4+ cell
count < 200 cells/mm3. Only a small minority (32.2%) of
the patients on HAART were found to have CD4+ counts >
200 cells/mm3. Among those who were not on HAART
51.3% had CD4+ cell count < 200 cells/mm3 while the rest
in the group had CD4+ cell count > 200 cells/mm3. How-
ever, the majority (70.3%) of adult patients on HAART
had CD4+ cell count < 200 cells/mm3 while only minority
(36.4%) of the children on HAART had CD4+ cell count <
200 cells/mm3. The mean difference of CD4+ cell counts
Table 2: Occurrence of HIV-associated oral lesions among children and adults
Oral lesion Children (2–17 yrs) n (%) Adults (18–67 yrs) n (%) Total (n = 532) n (%)
Oral candidiasis 6 (11.8) 119 (24.7) 125 (23.5)
Hyperpigmentation 0 (0) 25 (5.2) 25 (4.7)
Enlarged Parotid gland 10 (19.6) 11 (2.3) 21 (3.9)
Oral Kaposi's sarcoma 2 (3.9) 15 (3.1) 17 (3.2)
Necrotizing Ulcerative gingivitis 0 (0) 13 (2.7) 13 (2.4)
Oral hairy leukoplakia 2 (3.9) 10 (0.6) 12 (2.3)
Herpes simplex lesions 7 (2.2) 2 (2.1) 9 (1.7)
Recurrent ulcers 0 (0) 4 (0.8) 4 (0.8)
Oral warts 1 (2.0) 3 (0.6) 4 (0.8)
Bell's palsy 0 (0) 3 (0.6) 3 (0.6)
Herpes zoster face 0 (0) 2 (0.4) 2 (0.4)
Odontogenic abscess 0 (0) 2 (0.4) 2 (0.4)
All oral lesions 21 (41.2) 189 (39.3) 210 (39.5)
Table 3: Comparison of oral lesions among children on HAART (n = 22) and those not on HAART (n = 29)
Type of oral lesions No. of oral lesions n (%) Unadjusted OR (95% CI) Adjusted OR (95% CI) p-value
Oral candidiasis
On HAART 0 (0.0) 0.0 (0.0–9.20) 0.0 (0.0–1.80) 0.80
Not on HAART 6 (20.7)
Enlarged Parotid gland
On HAART 4 (18.2) 0.8 (0.2–3.48) 0.9 (0.22–3.93) 0.82
Not on HAART 6 (20.7)
Oral Kaposi's sarcoma
On HAART 1 (4.5) 1.3 (0.08–22.6) 0.9 (0.05–17.4) 0.84
Not on HAART 1 (3.4)
Oral hairy leukoplakia
On HAART 0 (0.0) 0.0 (0.0–2.61) 0.0 (0.0–2.11) 0.88
Not on HAART 10 (6.9)
Herpes simplex lesions
On HAART 0 (0.0) 0.0 (0.0–1.52) 0.0 (0.0–7.30) 0.92
Not on HAART 1 (3.4)
Oral warts
On HAART 1 (4.5) - - 0.91
Not on HAART 0 (0.0)BMC Oral Health 2006, 6:12 http://www.biomedcentral.com/1472-6831/6/12
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between the adult and children on HAART and those not
on HAART was statistically significant (t = 3.94; 95% CI =
42.3 – 126.3; p < 0.01). In both HAART and non-HAART
receiving children and adult patients oral lesions occurred
more significantly among those with CD4+ cell count less
than 200 cell/mm3 (χ2 = 52.4; df = 2; p < 0.01). There was
a strong association between the WHO clinical stage of
HIV disease with the presence of oral lesions (χ2 = 121; df
= 3; p < 0.01), particularly oral candidiasis (χ2 = 112; df =
3; p < 0.01), oral Kaposi's sarcoma (χ2 = 121; df = 3; p <
0.01), and oral hairy leukoplakia (χ2 = 10; df = 3; p <
0.05).
Eighty-four (15.8%) patients had current systemic dis-
eases at the time of examination. Sixty-two (11.7%)
patients had pulmonary tuberculosis (TB) and were on
anti-tuberculosis treatment. Other systemic opportunistic
diseases encountered at the time of examination were;
pneumonia 14 (2.6%) patients and herpes zoster 8
(1.5%) patients. One hundred and thirty eight (25.9%)
reported history of herpes zoster infection, 84 patients
(15.8%) pneumonia while cryptococcal meningitis was
reported by only 10 patients (1.9%). There was a signifi-
cant association between occurrence of pulmonary TB
with oral lesions (χ2 = 6.9; df = 1; p < 0.01) and oral can-
didiasis (χ2 = 11.0; df = 1; p < 0.01) but not other systemic
diseases (P > 0.05). Oral lesions were not associated with
any of the investigated socio-demographic features except
for tobacco smoking (χ2 = 8.17; df = 2; p < 0.01).
Discussion
In the present study, the prevalence of HIV-associated oral
lesions in adult patients receiving HAART was signifi-
cantly reduced. The reduction was mainly attributed to
Table 4: Comparison of oral lesions among adults on HAART (n = 276) and those not on HAART (n = 205)
Type of oral lesions No. of oral lesions n (%) Unadjusted OR (95% CI) Adjusted OR (95% CI) p-value
Oral candidiasis
On HAART 41 (14.9) 0.28 (0.18– 0.17 (0.11–0.28) 0.00
Not on HAART 78 (38.0) 0.44)
Hyper pigmentation
On HAART 17 (6.2) 1.62 (0.68– 1.60 (0.67–3.81) 0.27
Not on HAART 8 (3.9) 3.82)
Enlarged Parotid gland
On HAART 6 (2.2) 0.89 (0.27– 0.92 (0.27–3.10) 0.85
Not on HAART 5 (4.9) 2.95)
Oral Kaposi's sarcoma
On HAART 5 (1.8) 0.36 (0.12– 0.29 (0.10–0.89) 0.06
Not on HAART 10 (4.9) 1.06) *(0.03)
Necrotizing Ulcerative gingivitis
On HAART 5 (1.7) 0.45 (0.15–1.41) 0.37 (0.12–1.15) 0.17
Not on HAART 8 (3.4)
Oral hairy leukoplakia
On HAART 2 (0.7) 0.18 (0.04– 0.15 (0.03–0.70) 0.03
Not on HAART 8 (3.9) 0.85)
Herpes simplex lesions
On HAART 3 (1.1) 0.44 (0.10– 0.39 (0.09–1.69) 0.26
Not on HAART 5 (2.4) 1.86)
Recurrent ulcers
On HAART 1 (0.4) 0.24 (0.02– 0.22 (0.02–2.15) 0.22
Not on HAART 3 (1.54) 2.37)
Oral warts
On HAART 2 (0.7) 1.49 (0.13– 1.44 (0.13–16.4) 0.75
Not on HAART 1 (0.5) 16.5)
Bell's palsy
On HAART 0 (0.0) - - 0.84
Not on HAART 3 (1.5)
Herpes zoster face
On HAART 0 (0.0) - - 0.85
Not on HAART 2 (0.9)
Odontogenic abscess
On HAART 1 (0.4) 0.74 (0.04–11.9) 0.78 (0.05–13.0) 0.83
Not on HAART 1 (0.5)
* p-value obtained after adjusting for CD4+ cell counts.BMC Oral Health 2006, 6:12 http://www.biomedcentral.com/1472-6831/6/12
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the reduction of oral candidiasis and oral hairy leukopla-
kia among adult patients. This finding is consistent with
observations in other studies that have shown significant
reduction in these oral lesions associated with HAART
usage, linked to the improved immune status of patients
[12,13,15-22]. Notably, patients on HAART for the dura-
tion of more than six months had significantly lower prev-
alence of oral lesions (OR = 0.53; 95% CI 0.29–0.97; p <
0.05) and specifically oral candidiasis (OR = 0.53; 95% CI
0.29–0.97; p = 0.04). There was, however, no significant
association between the type of HAART regimen and pres-
ence of oral lesions, most probably due to the fact that
most of our patients (76.8%) were on one type of HAART
consisting of stavudine, lamivudine and nevirapine, and
that only one patient had a HAART combination contain-
ing PI. We found no significant difference in prevalence of
oral lesions between children on HAART and those not on
HAART (Table 3), similar to other studies [26,27]. The
occurrence of HIV-associated oral in children is an issue
that requires further investigation as the results of differ-
ent studies have produced conflicting results. In one study
there was no direct relationship between prevalence of
oral lesions, severe immunodepression, and/or viral load
> 100000 copies in children who were perinataly infected
with HIV [40].
There were no significant difference in prevalence of oral
lesions between adults (39.3%) and children (41.2%), (p
> 0.05). However, a significantly higher prevalence of
enlargement of parotid glands in children and oral candi-
diasis in adults was observed, which is in keeping with the
findings of Greenspan et al. 1992 [37].
Mucosal hyperpigmentation, which was the second most
prevalent oral lesions after oral candidiasis with a preva-
lence of 4.7%, occurred at higher, but non-significant
magnitude, among adult patients who were on HAART.
The reported prevalence of mucosal hyperpigmentation
compares with a prevalence of 6% among HIV/AIDS
patients in Kenya [9]. The higher prevalence of mucosal
hyperpigmentation in patients on HAART has been linked
with increased melanin production in the epithelium
associated with increased release of á-melanocyte-stimu-
lating hormone (á – MSH) [41] as a result of systemic
ketoconazole and zidovudine therapy [42,43]. In the
present study 20% (5/25) of patients with mucosal hyper-
pigmentation were on HAART combination containing
zidovudine.
Likewise, there was insignificant increase in oral papillo-
mata [oral warts] in patients on HAART as compared to
the non-HAART group. The increase in oral warts among
patients on HAART has been associated with immune
reconstitution [18,23-25]. The lack of significant associa-
tion between oral wart and HAART usage observed in the
present study could be due to the short period of the
administration of HAART as majority of patients were on
HAART for one to six months.
There were no differences in the prevalence of other oral
lesions including enlarged parotid glands, necrotizing
ulcerative gingivitis, recurrent ulcers, Bell's palsy and her-
pes zoster of the face between HAART and non-HAART
groups (p > 0.05). This could be explained by the fact that
most of these lesions are classified as being less com-
monly associated with HIV [44] and therefore, their prev-
alence even in the non-HAART receiving group was small.
The use of traditional medicine among our patients was
high (11.7%), which is approximately one in eight
patients, an observation that is in line with that reported
earlier in Tanzania [45]. Although no significant associa-
tion was found between occurrences of oral lesions and
use of traditional medicine (Table 1) there is still a need
for further studies since many people with HIV/AIDS use
traditional medicine in addition to HAART. It is crucial to
learn more about the nature and composition of these
plant medicines and their potential interactions with
drugs that are used for management of HIV/AIDS and its
associated opportunistic diseases.
In this study, 15.8% of patients diagnosed to have sys-
temic diseases such as tuberculosis, pneumonia and her-
pes zoster at the time of examination. However, the only
significant association found was between pulmonary TB
and oral lesions, specifically oral candidiasis (p <= 0.01)
Table 5: CD4+ cell counts of Patients on HAART and those not on HAART
Patients on HAART (n = 298) Patients without HAART (n = 234)
n (%) Mean SD n (%) Mean SD
CD4+ cell count (cells/mm3)
<200 202(67.8) 84.0 62.1 120 (51.3) 65.2 57.0
200–500 80(26.8) 296.0 75.0 84 (35.9) 314.4 90.2
>500 16(5.4) 714.1 207.1 30 (12.8) 879.9 415.2
Total 298 174.8 177.5 234 259.1 310.0 470
Student's t-test for comparing means; (t = 3.94; 95% CI = 42.3 – 126.3; p = 0.00).BMC Oral Health 2006, 6:12 http://www.biomedcentral.com/1472-6831/6/12
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(Table 6). This association possibly reflects immune dete-
rioration in patients with oral candidiasis and TB. This
finding, which is in keeping with that of Nittayananta et
al. 2002 [46] who found significant association between
the occurrence of TB and the presence of oral candidiasis
(OR 2.8; 95% CI 1.6–4.8; P < 0.01), and positive predic-
tive values of any oral lesions and oral candidiasis in pre-
dicting TB of 87% (95% CI 73.0–94.6) and 67% (95% CI
51.9–80.0), respectively seem to imply that oral candidia-
sis might be used as an additional clinical marker for TB
together with clinical presentation of weight loss with
night sweats and chest symptoms. Majority (25.9%)
reported history of herpes zoster infection, 84 patients
(15.8%) pneumonia while cryptococcal meningitis was
reported by only 10 patients (1.9%). However, there was
no statistically significant difference between prevalence
of oral lesions and history of opportunistic systemic dis-
eases (P > 0.05). The limitation on this part of the study
was dependency on patients to recall previous opportun-
istic disease.
Lastly, the significant association between occurrence of
oral lesions with CD4+ counts < 200 cells/mm3 and WHO
clinical stage of HIV disease (Table 1) found in this study
underscores the prognostic significance of these manifes-
tations in HIV disease.
Conclusion
In this group of HIV-infected patients, adult patients
receiving HAART predominantly combination of stavu-
dine, lamivudine and nevirapine for a period of less than
a year, had a significantly lower prevalence of oral lesions,
particularly oral candidiasis and oral hairy leukoplakia
that was observed. There was also an insignificant increase
in prevalence of oral warts and mucosal hyper pigmenta-
tion, while the prevalence of other oral lesions was
unchanged. However there was no significant change in
occurrence of oral lesions in children receiving HAART.
More studies preferably longitudinal need to be con-
ducted for longer periods of time in order to get a better
picture on the efficacy of HAART in reducing oral lesions
in both children and adults in our setting.
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